PLX3397 (Pexidartinib)
- CAS No.
- 1029044-16-3
- Chemical Name:
- PLX3397 (Pexidartinib)
- Synonyms
- Pexidartinib;Turalio;PLX-3397;Pexidartinib (PLX3397);[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine;PLX339;CML261;FP113);CS-1695;Peridartinib
- CBNumber:
- CB22742977
- Molecular Formula:
- C20H15ClF3N5
- Molecular Weight:
- 417.81
- MOL File:
- 1029044-16-3.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/5/24 17:07:44
| Density | 1.458±0.06 g/cm3(Predicted) |
|---|---|
| storage temp. | -20°C |
| solubility | Soluble in DMSO (up to at least 10 mg/ml) |
| pka | 12.81±0.40(Predicted) |
| form | solid |
| color | White |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. |
| CAS DataBase Reference | 1029044-16-3 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
PLX3397 (Pexidartinib) Chemical Properties,Uses,Production
Description
Colony stimulating factor 1 (CSF1) is a cytokine that is involved in the recruitment and activation of tissue macrophages. It exerts these effects by binding to its corresponding receptor tyrosine kinase, the cFMS/CSF1 receptor (CSF1R). Pexidartinib is a brain-penetrant inhibitor of CSF1R, as well as c-Kit and FLT3 (IC50s = 20, 10, and 160 nM in vitro, respectively). It has been used in combination with paclitaxel to block macrophage recruitment in mammary tumor-bearing mice, thus slowing primary tumor development and metastasis. Pexidartinib has also been used to block microglial stimulation of glioblastoma invasion in both cell culture and a mouse model of glioblastoma multiforme.
Uses
Pexidartinib is RTK inhibitor. It can be used in pharmacological activity, therapeutic use, and biological study of inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
brand name
Turalio
General Description
Class: receptor tyrosine kinase; Treatment: TGCT; Other name: PLX3397; Elimination half-life = 26.6 h; Protein binding = >99%
Clinical Use
Pexidartinib is used for the treatment of adult patients with symptomatic tenosynovial giant cell tumour (TGCT) associated with severe morbidity or functional limitation not ameliorated by surgery.
target
Primary targets: CSF1R, KIT, FLT3
PLX3397 (Pexidartinib) Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| Hangzhou FandaChem Co.,Ltd. | 008657128800458; +8615858145714 | China | 9338 | 55 | Inquiry |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | China | 32760 | 60 | Inquiry |
| BOC Sciences | +1-631-485-4226 | United States | 19553 | 58 | Inquiry |
| career henan chemical co | +86-0371-86658258 +8613203830695 | China | 29826 | 58 | Inquiry |
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | United States | 19892 | 58 | Inquiry |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | China | 26216 | 58 | Inquiry |
| Finetech Industry Limited | +86-27-87465837 +8618971612321 | China | 9626 | 58 | Inquiry |
| Baoji Guokang Bio-Technology Co., Ltd. | 0917-3909592 13892490616 | China | 9326 | 58 | Inquiry |
Related articles
- How to synthesize PLX3397 (Pexidartinib)?
- ?Pexidartinib (PLX3397) is a novel, orally available small molecule tyrosine kinase inhibitor (TKI) with potent and selective ....
- Jan 22，2024
- What is PLX3397 (Pexidartinib)?
- PLX3397 (Pexidartinib) is a small-molecule, oral, potent multi-targeted receptor tyrosine kinase (RTK) inhibitor of CSF-1R, Ki....
- Feb 24，2020
- PLX3397 (Pexidartinib)
- Pexidartinib (TURALIO) is a novel, orally available small molecule tyrosine kinase inhibitor (TKI) with potent and selective a....
- Dec 11，2019